Zymeworks Inc.
ZYMEZymeworks Inc. (ZYME) is a biotechnology company specializing in the development of next-generation multifunctional antibodies for the treatment of cancer and other diseases. Founded in 2008 and headquartered in Vancouver, Canada, Zymeworks utilizes proprietary platform technologies to engineer novel therapeutic candidates, aiming to improve efficacy and safety profiles for targeted therapies.
Company News
Zymeworks Inc. will participate in two upcoming healthcare investor conferences in Miami, including one-on-one meetings and fireside chats, highlighting their biotechnology portfolio and licensed healthcare assets.
Zymeworks, Jazz Pharmaceuticals, and BeOne Medicines reported positive Phase 3 trial results for Ziihera in treating HER2-positive gastroesophageal adenocarcinoma, demonstrating significant improvements in progression-free and overall survival.
Zymeworks (ZYME) delivered earnings and revenue surprises of -35.48% and 44.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks has a strong financial position, with a robust liquidity position and a cash runway that extends into 2027. Learn why ZYME stock is a Buy.
These biotech companies are seeing a spike in revenue growth.
